aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...

intervaliT. aseT SemTxvevaSi cofis sawinaaRmdego imunoglobulinis
gamoyeneba saWiro ar aris. igive wesebi vrceldeba vaqcinirebul pirebze,
romelTa maneitralizebeli antisxeulebis titri 0.5 se/ml-Si an metia.
adamianis diploidur-ujreduli vaqcina miCneulia oqros standartad.
jandacvis msoflio organizaciis mixedviT aucilebelia ujreduli
vaqcinis minimum 2.5se-s gamoyeneba TiToeuli dozirebisas. miuxedavad
maRali efeqturobisa ujreduli vaqciniT eqspoziciis Semdgom
Catarebuli milioni mkurnalobidan erTi SeiZleba aRmoCndes uSedego.
analizi gviCvenebs, rom uSedego mkurnaloba, rogorc wesi,
dakavSirebulia mniSvnelovan dazianebasTan Tavis an mezobel midamoSi,
an arasworad Catarebul mkurnalobasTan.
eqspoziciis Semdgomi mkurnalobis sruli kursi nervuli qsovilis
vaqcinis gamoyenebiT gulisxmobs 23 ineqciisgan Semdgari imunizaciis
gaxangrZlivebul da mtkivneul kurss. amasTan nervuli qsovilis
vaqcinebi ujredul vaqcinebTan SedarebiT neklebad efeqturia. amrigad,
aRniSnuli vaqcina eqspoziciis Semdgomi imunizaciisaTvis rekomendebuli
ar aris.
27 2.5 mlrd adamianze meti cxovrobs cofis endemur arealSi(afrika, azia, samxreT
amerika).yovelwliurad saSualod 50 000 adamiani iRupeba cofiT da 10 mln-ze met
adamians utardeba eqspoziciis Semdgomi profilaqtika. 5-15 wlis asakis bavsvebi
imyofebian maRali riskis qveS.
28 calkeul asakobriv jgufebSi Catarebuli kvlevebis mixedviT daavadebis maRali
riski aqvT ganviTarebadi qveynebis cofis endemur areebSi mcxovreb bavSvebs.
29 ZiriTadad rekomendebulia 1 wlis Semdeg damatebiti doza bustirebisTvis;
vaqcinacia yovel 5 weliwadSi maRali riskis pirebisTvis; cofis virusis sawinaaRmdego
antisxeulebis perioduli gamokvleva (proteqciisaTvis aucilebeli titria >0.5se/ml)
gamoyenebuli litraturis CamonaTvali:
1. Onorato IM, Markowitz LE, Oxtoby MJ. Childhood immunization, vaccine-preventable diseases and
infection with human immunodeficiency virus. The Pediatric Infectious Disease Journal, 1988, 6:588–
595.
2. Opravil M et al. Poor antibody response after tetanus and pneumococcal vaccination in
immunocompromised, HIV-infected patients. Clinical and Experimental Immunology, 1991, 84(2):185–189.
3. Borkowsky W et al. Antibody responses to bacterial toxoids in children infected with human
immunodeficiency virus. The Journal of Pediatrics, 1987, 110:563–566.
4. Huang KL et al. Antibody responses after influenza and pneumococcal immunization in HIV-infected
homosexual men. JAMA, 1987, 257:2047–2050.
5. Klein RS et al. Responses to pneumococcal vaccine among asymptomatic heterosexual partners of persons
with AIDS and intravenous drug users infected with human immunodeficiency virus. Journal of
Infectious Diseases, 1989, 160:826–831.
6. TB/HIV: a clinical manual, 2nd ed. Geneva, WHO, 2004.
7. Global Advisory Committee on Vaccine Safety. Safety of BCG vaccination in immunocompromised
individuals. Weekly Epidemiological Record, 2003, 32(8):283 (http://www.who.int/wer/2003/en/wer7832.
pdf, accessed 25 June 2006).
131